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Activation of the coagulation system by contact of circulating blood with tissue factor, a component of the extrinsic blood coagulation pathway that is produced in the vessel wall, may represent a pathway for the initiation of thrombosis in atherosclerotic vessels. This hypothesis was tested in vivo in a rabbit femoral artery eversion (inside-out) graft model, in which the adventitia, with its tissue factor, was exposed to circulating blood. Intra-arterial infusion of a neutralizing monoclonal antibody against tissue factor (D3) at a rate of 12 mg/kg over 15 minutes prevented thrombosis of a 7-8-mm eversion graft within a 2-hour observation period in four of five rabbits, whereas with a control antibody infusion (MA-1SC5), occlusion occurred within 2 hours in five of six rabbits. In vitro immersion before reinsertion of the arterial segment in a solution containing 2 mg/ml of the control antibody for 30 minutes was associated with occlusion in all six rabbits, whereas pretreatment with D3 was associated with persistent patency in three of nine rabbits.
Stepwise logistic-regression analysis of the results with perfusion status as the dependent variable and type of antibody (D3 or MA-15C5), application method (infusion versus immersion), and graft segment length as independent variables yielded a significant difference in frequency of occlusion with the two antibodies (p=0.016). It is concluded that exposure of tissue factor to flowing blood may constitute a trigger mechanism for platelet-mediated arterial thrombosis. T issue factor is a glycoprotein present on the plasma membranes of many cells that normally are not in contact with blood. 1 When exposed to blood, tissue factor binds coagulation factors VII and Vila in the presence of Ca 2+ , and this complex activates blood coagulation factors IX and X. 2 -3 Thus, tissue factor plays a role in the activation of both the "intrinsic" and "extrinsic" pathways of blood coagulation. It has been suggested that tissue factor may represent the major initiator of in vivo coagulant pathways. 4 In normal blood vessels, tissue factor is synthesized in scattered cells in the tunica media and adventitia; in atherosclerotic vessels, however, tissue factor is also produced by foam cells, monocytes, and mesenchymal-like cells in the plaque intima. 5 It was suggested that deposition of tissue factor in the matrix of the necrotic core of atherosclerotic plaques may contribute to thrombosis associated with plaque rupture. Supported in part by ISCHEMIA SCOR grant HL-26205 from the National Heart, Lung, and Blood Institute, Bethesda, Md., and by a sponsored research agreement between Massachusetts General Hospital and Genentech Inc., South San Francisco, Calif.
The present study was carried out to investigate the role of tissue factor in the initiation of platelet-rich arterial thrombosis in a rabbit femoral arterial eversion graft model. 6 The role of tissue factor localized in the adventitia in the activation of blood coagulation was evaluated with a tissue factor-neutralizing murine monoclonal antibody (D3).
Methods

Reagents
The murine monoclonal antibody D3 directed against human tissue factor was produced and supplied by Genentech Inc., South San Francisco, Calif. A control antibody (MA-15C5) directed against human crosslinked fibrin but not cross-reacting with rabbit fibrin 7 was obtained from the Center for Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium. D-Phe-L-pro-L-arg chloromethyl ketone (PPACK) was purchased from Calbiochem, La Jolla, Calif. Heparin was purchased from Sinn, Cherry Hill, N.J., and aspirin for intravenous use from Synthelabs, Benelux, Brussels, Belgium.
Effect of Monoclonal Antibodies on Rabbit Tissue Factor In Vitro
The effect of the monoclonal antibodies D3 and MA-15C5 on the functional activity of rabbit tissue factor was evaluated in vitro in a prothrombin time assay. 
Femoral Artery Eversion Graft Thrombosis Model
The femoral artery thrombosis model in the rabbit has been described in detail elsewhere. 6 Briefly, New Zealand White rabbits weighing between 2.6 and 4.1 kg were anesthetized with sodium pentobarbital. The right brachial artery was cannulated for continuous blood pressure monitoring and the right brachial vein for intravenous administration of test material. A 4-6-mm segment from the right femoral artery was excised and everted (turned inside out). The segment was maintained in 1 ml physiological saline for 30 minutes for use in the experiments with intra-arterial administration of antibody. Alternatively, the segment was immersed in 1 ml phosphate-buffered saline containing 2 mg/ml antibody for use in the immersion experiments. The left femoral artery was dissected, and the left superficial epigastric artery was cannulated for intra-arterial administration of monoclonal antibody. The baseline blood pressure and blood flow were measured, and a blood sample was taken. Heparin was given as an intravenous bolus of 200 units/kg followed by 70 units/kg every hour. The left femoral artery was transsected midway between the inguinal ligament and the distal bifurcation. The everted segment from the right femoral artery was then inserted by end-to-end anastomosis into the transsected left femoral artery by using a surgical microscope and microsurgical techniques. The length of the everted reanastomosed segment was measured after restoration of the blood flow.
Experimental Protocols
The following experimental protocols were applied. First, in preliminary experiments D3 was infused intravenously over 15 minutes starting 10 minutes before the release of the vessel clamps. Second, D3 or MA-15C5 was given intra-arterially, with one quarter of the total dose given as a bolus 10 minutes before the release of the clamps and the remainder as a continuous infusion over 15 minutes, starting 1 minute before the restoration of blood flow. Third, the graft segment was immersed for 30 minutes in a solution containing 2 mg/ml D3 or 2 mg/ml MA-15C5. Additional experiments were performed in which the grafts were immersed in saline containing 0.1 mg/ml of the thrombin inhibitor PPACK or in saline containing both D3 and PPACK. Finally, graft segments immersed in the D3 solution were reanastomosed in rabbits pretreated with intravenous administration of 17 mg/kg aspirin, 1 hour before clamp release. The blood flow in the left femoral artery distal to the anastomosis was continuously recorded after release of the vessel clamps with an ultrasonic flowmeter (model T101, Transsonic Systems, Inc., Ithaca, N.Y.). When the flow decreased from a baseline value of 11-14 ml/min to <0.5 ml/min, the vessel was judged to be occluded. In all animals the blood flow was monitored for 2 hours.
Hematological Assays
Blood samples for determination of the prothrombin time and activated partial thromboplastin time were drawn into 0.01 M citrate and taken at baseline, 50 minutes after the release of the vessel clamps (1 hour after the start of the antibody infusion), and 1 hour later.
Pathological Examination
At the end of the experiment, occluded left femoral arteries were excised, fixed in 5% formaldehyde, sectioned longitudinally, and stained with hematoxylin and eosin. Some of the patent segments were subjected to perfusion-fixation with 0.1 M cacodylate-buffered 0.25% glutaraldehyde for scanning electron microscopy, as previously described. 8 Two femoral graft segments (one noneverted vessel segment and one everted segment) were fixed for immunocytochemistry studies by immersion in 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4, at 4°C for 2 hours and then immersed overnight in sterile phosphate-buffered saline containing 15% sucrose at 4°C. The tissues were then frozen in liquid nitrogen in a cryomold containing OCT embedding medium, sectioned on a cryostat to 5 fim, and thaw-mounted onto poly-L-h/sine-coated microscope slides. The slides were refrozen and stored at -70°C with dessicant until immunohistochemical analysis. The slides were thawed and stained with an antirabbit tissue factor polyclonal antibody (generously provided by Drs. V.J. Rao and S. Rappaport, University of California at San Diego, La Jolla, Calif.) at a dilution of 1/500. Immunohistochemistry was performed according to the manufacturer's instructions by using the Vectastain ABC alkaline phosphatase system (Vector Labs, Inc., Burlingame, Calif.). The final reaction product was stained with the alkaline phosphatase substrate kit 1 to give a final red stain, and the slides were counterstained with methyl green.
Statistical Analysis
The values are expressed as mean±SD. Fisher's exact text was used to compare the patency status of the vessels. Stepwise logistic-regression analysis was performed on the results of vessel patency status as follows. Three independent variables were included in the model, consisting of the type of antibody (D3 or MA-15C5), the method of application (infusion or immersion), and the segment length after reanastomosis, as well as the interaction between these variables. The dependent variable was perfusion status (patent versus occluded). The results were analyzed by using the BMDP statistical software program PLR (BMDP Statistical Software, Los Angeles, Calif.). Figure 1A illustrates the effect of the monoclonal antibody D3 on the clotting time of pooled citrated human plasma with mixtures of rabbit brain thromboplastin and calcium chloride. In the absence of antibody, Figure IB) either with or without a 15-minute preincubation produced clotting times very similar to those obtained with D3 in the absence of preincubation. These data thus indicate that a 15-minute preincubation of rabbit brain thromboplastin with D3 but not with MA-15C5 prolongs the clotting time to an extent similar to that obtained with a twofold dilution. Thus, under these conditions the effect of D3 corresponds to an apparent reduction of the rabbit brain thromboplastin activity by 50%.
Results
Effect of Monoclonal Antibodies D3 and MA-15C5 on Rabbit Tissue Factor In Vitro
Effects of Monoclonal Antibodies D3 and MA-15C5 on Rabbit Femoral Artery Eversion Graft Occlusion
Intravenous bolus injection of D3 antibody at a dose of 2.5 or 6.5 mg/kg failed to prevent thrombotic occlusion of the everted segment in two rabbits. With an intravenous bolus injection of 12 mg/kg D3, thrombosis was prevented in one of three animals only. Therefore, subsequent studies were carried out with an intraarterial infusion of D3 at a dose of 12 mg/kg (given as described in "Methods"). This intra-arterial infusion of D3 prevented thrombotic occlusion in four of five animals, whereas five of six rabbits treated with an intra-arterial infusion of the same dose of the control antibody MA-15C5 showed occlusion within 20 minutes (/?=0.08 by Fisher's exact test). When the graft segment was immersed for 30 minutes in 1 ml saline containing 2 mg/ml D3, thrombotic occlusion was prevented in three of nine animals, whereas all six rabbits, in which the graft segment was immersed in the control antibody for 30 minutes, were occluded within 10 minutes (p=0.22 by Fisher's exact test). The results of intra-arterial infusion and graft immersion experiments on femoral artery patency are summarized in Table 1 . Stepwise logistic-regression analysis of the perfusion status data performed as outlined in "Methods" yielded the following significance levels of the differences between the independent variables: antibody D3 versus MA-15C5, p=0.016; method of application,/?=0.041; and segment length,/?=0.334.
In a separate group of six animals in which the vessel segment was immersed for 30 minutes in 1 ml saline containing 0.1 mg/ml PPACK, a potent irreversible synthetic thrombin inhibitor, two rabbits showed persistent patency throughout the experiment (p=0A5 versus control group). When the graft segment was immersed in a mixture of D3 antibody and PPACK, thrombotic occlusion was prevented in four of six animals (/?=0.06 versus control group). When the femoral artery segment immersed in a solution containing 2 mg/ml D3 was reanastomosed in six rabbits pretreated with 17 mg/kg aspirin, occlusion occurred within 2 hours in three of six rabbits (/?=0.18 versus control group).
There were no significant changes in prothrombin time in any of the groups (data not shown). This indicates that the anti-tissue factor concentration in plasma after infusion of a dose of 12 mg/kg over 15 minutes did not significantly interfere with the in vitro prothrombin time assay. Activated partial thromboplas- SEM, scanning electron microscopy; H&E, hematoxylin and eosin staining; occ/pat, occluded or patent, respectively, as determined by blood flow measurement at the end of the observation period; OT/MT, occlusive or mural thrombus, respectively, as determined by SEM or H&E; PR, platelet-rich; ER, erythrocyte-rich; MPE, mixed thrombus with interfaced PR and ER zones. tin times were >100 seconds throughout the experiment in all animals.
Pathological Analysis
The results of pathological analysis are summarized in Table 2 . The extent of arterial thrombosis as determined by histology was graded as occlusive thrombus (OT) or mural thrombus (MT) and the composition of the thrombus as platelet rich (PR), erythrocyte rich (ER), or mixed, with interlaced platelet-rich and erythrocyte-rich zones (MPE). The OT examined in 17 animals (10 given the control antibody and seven given D3) consisted of: 1) primarily PR thrombus in five animals; 2) PR platelet plug at the anastomosis, with MPE thrombus or ER thrombus, in six animals; 3) MPE or ER thrombus in five animals; and 4) ER clot in one animal. The MT found in two rabbits with patent arteries by histology and in six rabbits by scanning electron microscopy was primarily PR in all animals. Typical examples of scanning electron photomicrographs of a patent artery in a rabbit treated with intra-arterial D3 are given in Figure 2 . In these arteries, aggregated platelets overlayered with some red cells but no fibrin deposition were observed, suggesting that administration of the antibody D3 abolished activation of the coagulation system on the everted arterial wall segment. A light photomicrograph of an occluded artery in a rabbit given the control antibody is represented in Figure 3 .
The presence of tissue factor in the arterial wall is illustrated by immunohistochemical analysis of an everted vessel (Figure 4 ). In agreement with previous data, 5 tissue factor is predominantly localized to the adventitial fibroblasts surrounding the femoral artery, which are presented to flowing blood after eversion.
Discussion
Atherosclerotic coronary artery disease constitutes the underlying pathogenetic mechanism of acute ischemic coronary syndromes.
9 " 12 The initiating event for the development of ischemia appears to be plaque rupture, the pathogenetic mechanism of which remains largely unexplained. 10 Plaque rupture initially causes platelet aggregation and subsequently leads to thrombus formation. Thrombosis may be either subocclusive or transiently occlusive and produce unstable angina, or persistently occlusive leading to myocardial infarction. 910 The mechanism of thrombus formation on ruptured plaques is probably complex, comprising activation of platelets as well as of the blood coagulation system 9 ' 13 and resulting in a thrombus that is variably composed of PR and ER zones. 9 Low-molecular-weight thrombin inhibitors but not heparin have a potent inhibitory effect on platelet-mediated arterial thrombosis, 6 -14 - 16 which is indicative of a pivotal role of thrombin in the pathogenesis of arterial occlusion. Thrombin formation may be initiated via either contact activation of the intrinsic blood coagulation system by subendothelial structures or activation by thromboplastin of the extrinsic coagulation system 13 and may be amplified by assembly of blood coagulation complexes, such as the prothrombinase complex on phospholipid membranes of activated platelets. 17 Normal endothelium does not contain tissue factor, an essential component for the initiation of the extrinsic pathway of blood coagulation. 20 Wilcox et al 5 have recently demonstrated that atherosclerotic plaque is rich in tissue factor, which by exposure to blood after plaque rupture might constitute an important mechanism of platelet aggregation and fibrin deposition.
The recent development of a neutralizing monoclonal antibody against human tissue factor that, as demonstrated in the present study, reduces the activity of rabbit tissue factor in brain thromboplastin ( Figure 1 ) and reacts with tissue factor in vessel wall sections provides a useful tool to test the potential contribution of tissue factor-mediated activation of blood coagulation to arterial thrombosis in vivo. However, crossreactivity of the anti-human tissue factor monoclonal antibody with rabbit tissue factor was only limited, which may have contributed to the requirement of high intra-arterial doses to prevent thrombotic occlusion. We used a rabbit femoral artery eversion graft model in which we have previously shown that stable thrombosis primarily by PR material occurs spontaneously. 21 Attempts to prevent thrombotic occlusion in this model with the use of aspirin or heparin, alone or in combination, have failed. 6 With a specific thrombin inhibitor, however, especially when combined with aspirin, it was possible not only to prevent platelet-mediated eversion graft thrombosis but also to maintain patency after disappearance of the inhibitor from blood. 22 This model for thrombin-initiated platelet-mediated arterial thrombosis was used in the present study because the adventitia, which is rich in tissue factor, might simulate the tissue factor-mediated thrombogenicity of an atherosclerotic plaque and allow evaluation of its contribution to the development of platelet-mediated arterial thrombosis. Inhibition of tissue factor with a neutralizing monoclonal antibody produced a significant (/7=0.016) reduction of the frequency of occlusion of the everted arterial segment compared with a control antibody. However, in this highly thrombogenic model it was necessary to infuse the antibody intra-arterially at a high rate. Therefore, experiments were carried out with in vitro immersion of the segment in antibody-containing solution. This again produced a reduction but not an elimination of thrombogenicity. These results suggest that either the tissue factor-mediated pathway is not the only initiating mechanism for arterial thrombosis or inhibition of rabbit tissue factor with relatively weakly cross-reacting anti-human tissue factor antibody may have been incomplete. Possibly, other pathways of thrombin generation (e.g., contact activation of blood coagulation) or of platelet aggregation (e.g., contact with exposed collagen) may also contribute to thrombogenicity.
To eliminate the contribution of thrombin formed during preparation of the eversion graft to arterial graft thrombosis after anastomosis, graft segments were immersed in a solution of PPACK, a potent irreversible inhibitor of thrombin. Whereas immersion in D3 prevented thrombosis in three of nine rabbits and immersion in PPACK prevented thrombosis in two of six rabbits, their combination did not completely abolish thrombosis, which still occurred in two of six rabbits (p=0.06 versus control rabbits). It is possible that thrombin inhibition with PPACK had some additional effect on the frequency of graft occlusion, but to demonstrate a marginal effect with statistical significance, a large number of experiments would have to be carried out. Nonetheless, these observations are consistent with the hypothesis that tissue factor-mediated thrombin generation is a significant but not the only mechanism of arterial graft thrombosis.
Alternatively, immersed segments were reanastomosed in rabbits treated with intravenous aspirin at a dose that totally abolished arachidonic acid-induced platelet aggregation. 22 Again, the antithrombotic effect of the combination was not markedly superior to that observed in the absence of aspirin.
In conclusion, our study shows that platelet-mediated arterial thrombosis in the rabbit femoral artery eversion graft model is significantly reduced but not abolished by at least partial neutralization of tissue factor in the adventitia. This finding suggests that tissue factorinitiated activation of the coagulation system may be a significant pathogenetic mechanism in platelet-mediated thrombosis. The study therefore confirms and extends recent findings on the pivotal role of thrombin in platelet-mediated thrombosis and provides in vivo support for the hypothesis that the generation of tissue factor in atherosclerotic plaque may contribute to its thrombogenicity after plaque rupture.
